The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular landscape of fibrolamellar carcinoma (FLC): Beyond the DNAJB1-PRKACA chimera.
 
Imane Hassan El Dika
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - Cancer Genetics; Sequenom
 
Maria E. Arcila
No Relationships to Disclose
 
Ryma Benayed
No Relationships to Disclose
 
James J. Harding
No Relationships to Disclose
 
Matthew Rusek
No Relationships to Disclose
 
Emily Valentino
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)
 
Leonard Saltz
Consulting or Advisory Role - Abbvie; Lilly; McNeil PPC (I)
Research Funding - Taiho Pharmaceutical
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Medimmune; Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris